Affiliation:
1. Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Boston, MA 02111, USA
Abstract
Despite the increasing availability of antibiotics with activity against pathogens that cause community-acquired pneumonia (CAP), CAP remains a major cause of morbidity, hospital admissions and re-admissions, and mortality. Lefamulin is a novel pleuromutilin antibiotic with potent in vitro activity against both typical and atypical CAP pathogens. In this review of the medical literature, we summarize the available information, including mounting clinical evidence, about lefamulin and its potential value in CAP.
Subject
Microbiology (medical),Microbiology
Reference34 articles.
1. Centers for Disease Control and Prevention website (2018). www.cdc.gov/nchs/fastats/pneumonia.htm
2. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults
3. Antibiotic Resistance Threats in the United States, 2013. U.S. Department of Health and Human Services Centers for Disease Control and Prevention (2013). www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf
4. Nabriva Therapeutics website (2018). www.nabriva.com/pipeline-research
5. Are pleuromutilin antibiotics finally fit for human use?
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献